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Abstract
It is widely believed that targeting the tumour-initiating cancer stem cell (CSC) component of malignancy has great
therapeutic potential, particularly in therapy-resistant disease. However, despite concerted efforts, CSC-targeting strategies
have not been efficiently translated to the clinic. This is partly due to our incomplete understanding of the mechanisms
underlying CSC therapy-resistance. In particular, the relationship between therapy-resistance and the organisation of CSCs
as Stem-Progenitor-Differentiated cell hierarchies has not been widely studied. In this review we argue that modern
clinical strategies should appreciate that the CSC hierarchy is a dynamic target that contains sensitive and
resistant components and expresses a collection of therapy-resisting mechanisms. We propose that the CSC
hierarchy at primary presentation changes in response to clinical intervention, resulting in a recurrent malignancy that
should be targeted differently. As such, addressing the hierarchical organisation of CSCs into our bench-side theory
should expedite translation of CSC-targeting to bed-side practice. In conclusion, we discuss strategies through which
we can catch these moving clinical targets to specifically compromise therapy-resistant disease.
Background
Tumours are heterogeneous collections of cells, only
some of which are capable of initiating tumourigenesis.
In many different types of malignancy, these ‘tumour-
initiating’ cells have been shown to display the stem
cell-like properties of self-renewal, differentiation and
the development of (malignant) tissues. This has led to
tumour-initiating cells being collectively referred to as
‘Cancer Stem Cells’ (CSCs), and interest in targeting
cancer stemness as a clinical strategy. CSCs have been
shown to be highly-resistant to conventional cancer
therapies such as chemotherapy and radiotherapy. While
the targeting of CSC mechanisms has been shown to re-
duce therapy-resistance in many cell culture models, this
has not been successfully translated to the clinic. In this
review we will discuss successes and limitations in tar-
geting CSC therapy-resistance mechanisms. We will
argue that clinical-failure in this area may be partly due
to a poor understanding of the plastic nature of the
complex hierarchies into which CSCs are organised in
vivo. Finally, we will conclude by arguing that clinical
translation will be hastened by an appreciation of
therapy-resistant CSC populations as moving, rather
than fixed clinical targets.
Stem cells, hierarchies, development, growth and
repair
Stem cells (SCs) are defined as cells that can self-renew,
produce different cell types during a cell division process
known as ‘differentiation’, and re-generate the tissues
from which they were generated [Reviewed in 1]. These
properties are not shared by non-SCs [2]. SCs have the
capacity for long-term proliferation in the undifferenti-
ated state to perpetuate the SC pool throughout life
(self-renewal). Depending on the body’s requirements,
SCs can produce two undifferentiated cells through sym-
metrical self-renewal or two differentiated cells through
symmetrical differentiation. Additionally, SCs often pro-
duce one undifferentiated cell and one differentiated cell
simultaneously, in a process referred to as ‘asymmetric
division’. The function of asymmetric division is to re-
tain the pool of self-renewing cells while producing
differentiating cells [3–5]. SCs use extensive rounds of
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self-renewal and differentiation to produce de novo
tissues in the embryo and for growth and repair of
tissues post-embryonically.
SCs are primarily characterised by their potency, a
term used to refer to the number of cell and tissue types
they can produce through differentiation. SCs are
broadly categorised as Embryonic SCs (ESCs) and adult
SCs. ESCs are found in the inner cell mass of the devel-
oping blastocyst and their primary function is to pro-
duce the tissues that compromise the body [6–8]. This
property is referred to as pluripotency, which is defined
as the ability to produce cells representative of all three
germ layers (endoderm, mesoderm and ectoderm [9]). In
contrast, adult SCs are located within specific niches in
each adult tissue and function to produce new cells for
growth and repair. Adult SCs are generally multipotent,
which refers to their ability to generate several related
cell types of relevance to their location. The best studied
examples of the adult SC are the bone marrow SCs
(BMSCs) of which there are two types: haematopoi-
etic SCs, which produce the different types of blood
cell, and mesenchymal stem/stromal cells (MSCs),
which produce bone-related structural cells such as
adipocytes, chondrocytes and osteoblasts [10].
In recent years it has become clear that SCs produce
their differentiated progeny through one or more inter-
mediaries known as (‘committed’) ‘Progenitors’. Progeni-
tors are themselves SCs (can self-renew and differentiate),
and are the work horses of tissuegenesis. However, pro-
genitors are less potent than the parent SC that produces
them, and in healthy tissues have a more limited prolifera-
tion potential [Reviewed in 1]. The concept of hierarchical
arrangement of SCs was first described in bone marrow
research. It is now known that HSCs and MSCs generate
their repertoire of cell types through a number of inter-
mediaries [11–14]. For example HSCs produce lymphoid
and myeloid progenitors, which respectively develop to
produce lymphocytes and myeloid cells such as red blood
cells, neutrophils and macrophages. The Stem-Progenitor-
Differentiated cell model has complicated SC analysis and,
in particular, the identification and isolation of novel SCs.
This is because it is now understood that most tissues
contain multiple different SC types acting independently
and inter-dependently. Unfortunately for CSC research,
tumour tissue is similarly complicated, which has hin-
dered clinical translation of CSC-targeting.
Cancer stem cells, hierarchies and tumourigenesis
The concept of the CSC dates back to the study of the
gonadal tumour ‘Embryonal Carcinoma’ (EC) by pathol-
ogists in the late 1890s [15, 16]. In describing the tissues
within ECs as a disorganised caricature of the embryo, it
was proposed that these tumours developed from ESC-
like pluripotent cells. With the development of immune-
compromised animal models in the 1960s, Kleinsmith
and Pierce [9] showed that a single EC (stem) cell, the
malignant counterpart of an ESC [15, 16], was sufficient
for tumourigenesis. Although the term CSC was not
used at the time, this was the first experimental proof of
a CSC, and was pivotal to the Leukaemia SC (LSC) work
that led to the declaration of the CSC theory and the
current intense interest in CSCs. EC research was com-
plimented by extensive LSC research, where the term
CSC was first described. Following identification of LSCs
by Bonnet and Dick [17] as the tumour-initiating cells of
acute myeloid leukaemia, CSCs were later isolated from
solid tumours, such as breast cancer and brain tumours
[18, 19]. Since these seminal publications, CSCs have
been isolated from many solid cancers, including lung,
colon, prostate, ovarian cancer and melanoma, among
others [20–24]. It is now well-established that tumour-
initiating cells from many, if not all, malignancies share
some of the properties of SCs [1, 25, 26]. Today, CSCs
are defined by the SC properties of self-renewal, differ-
entiation and the ability to efficiently (from low cell
numbers) re-generate their original malignancy in vivo.
Additionally, CSCs are known to resist standard inter-
ventions such as chemotherapy and radiotherapy
[Reviewed in 27].
In 2001, a seminal article by the Weissman group
highlighted the need to develop CSC-targeting strategies
to complement existing anti-cancer treatments [25]. It
was proposed that the persistence of CSCs post-
intervention was a likely explanation for recurrence. In
the early days of CSC Theory, tumours were modelled
as broadly consisting of a small population of tumour-
initiating CSCs, surrounded by their differentiation pro-
geny, which formed the bulk of the tumour. However,
more recently this has been complicated by an appreci-
ation that CSCs, like SCs, are organised hierarchically
[Reviewed in 26]. The organisation of CSCs as Stem-
Progenitor-Differentiated cell hierarchies was first de-
scribed in LSCs [17]. However, in the 20 years since,
relatively few hierarchies were characterised in specific
malignancies. This was primarily due to the difficulty as-
sociated with identification and hierarchy-elucidation of
specific CSCs from the heterogeneous population of
CSCs found in tumours. Thankfully, rapid advances in
technologies such as flow cytometry in recent years have
permitted elucidation of CSCs in cancers such as skin,
glioblastoma and liver [28–31]. Current models indicate
that CSCs are organised as tree-like hierarchies (Fig. 1).
At the top of the CSC hierarchy, the ‘Apex CSC’ is be-
lieved to spend very little time in an active state and, in-
stead, primarily resides in a quiescent G0 state outside
the cell cycle. In contrast, quiescence does not appear to
be a property of progenitors CSCs. Mechanistically, it is
believed that tumour-initiation involves three different
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stages (Fig. 1). First, apex CSCs enter a highly prolifera-
tive state, which results in the production of a popula-
tion of lower potency Progenitor CSCs that is sufficient
to continue tumour development. Secondly, apex CSCs
enter quiescence while CSC progenitors undergo exten-
sive asymmetric division to produce the mature, specia-
lised cells that constitute the bulk of the tumour. Finally,
CSC progenitor function slows while the tumour enters
a process of maturation, where differentiated cell struc-
tures such as vasculature are completed. This may indi-
cate a link between CSC activity and tumour grade:
tumours that have not entered this maturation stage
present as higher grade malignancies and are associated
with worse prognosis due to their more proliferative
phenotype.
Ovarian cancer hierarchy
An interesting and illustrative example of the complex
organisation of CSCs as hierarchies is the elucidation of
these aspects of ovarian cancer in recent years. To date,
several groups have described ovarian CSCs (ovCSCs
[32–36]). However, many of these ovCSCs express differ-
ent CSC markers, which reflect their identification in
different models of a malignancy that is now considered
to be a collection of diseases. For example, Chen et al.
[35] and Silva et al. [33] have described CD44+/CD117+
and ALDH+/CD133+ ovCSCs, respectively (CD: ‘Cluster
of Differentiation’; ALDH: Aldehyde Dehydrogenase).
Subsequently, several studies have described ovCSCs
based on comparison of cells expressing specific markers
[32–36]. Despite the diverse nature of the markers,
many ovCSC studies were combined in a consensus
model for ovarian cancer proposed by Burgos-Ojeda
et al. [37]. In recent years, the first ovCSC hierarchy has
been described [33, 38]. In this work, single cell asym-
metric division (SCAD) assays [Reviewed in 1] were used
to describe a four-population hierarchy based on the ex-
pression of the stem cell markers ALDH and CD133. In
this Stem-Progenitor-Differentiated cell model, highly-
tumourigenic ALDH+/CD133+ CSCs can produce less-
tumourigenic ALDH+/CD133− Progenitor CSCs, which
can in turn produce non-tumourigenic ALDH−/CD133−
Differentiated CSCs.
Cancer stem cells and therapy-resistance
In early CSC Theory there was already an appreciation
that CSCs were therapy-resistant [25]. The clear implica-
tion from this was that therapy-resistant CSCs could
Fig. 1 The Role of the CSC Hierarchy in Tumourigenesis. a Cancer Stem Cell (CSC) Theory indicates that tumourigenesis begins with rapid proliferation of
stem cell-like tumour-initiating cells known as CSCs (Orange). Once a pool of CSCs has been established, less-potent ‘Progenitor CSCs’ are produced via
differentiation, which our data indicate can be sensitive (white) or (green) resistant to conventional cancer therapies. These Progenitor CSCs differentiate to
produce the mature cells (Brown) that constitute the bulk of the primary tumour. As the tumour becomes established, active CSCs (Orange) can enter a
dormant state known as Quiescence (Red). b We propose an alternative model for hierarchical CSC structure where both CSCs and Progenitors can be
sensitive or resistant to standard cancer therapies. Clinical-targeting of all CSC and Progenitor types is likely to compromise tumourigesis,
which is an attractive clinical strategy. However, to efficiently treat refractory disease, this model suggests that it may be important to identify, model
and target the specific therapy-resistant component(s) of the CSC hierarchy
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survive clinical intervention to regenerate recurrent dis-
ease through their tumour-initiation properties. It was
proposed that therapy-resistant CSCs should be targeted
in combination with conventional interventions as part
of an overall anti-cancer strategy [25]. In subsequent
years, this was largely interpreted as an indication that
all CSCs were broadly resistant to all therapies. In the
absence of models of CSC hierarchies, this was a reason-
able view. This model was furthered by considerable evi-
dence across many malignancies that indicated that
whenever a CSC was identified, it displayed therapy-
resistant properties. For example, it was found that cells
positive for the CSC marker ALDH isolated from lung
cancer cells lines demonstrated a high resistance to mul-
tiple chemotherapeutic agents (Cisplatin, Gemcitabine,
Vinorelbine, Docetaxel, Doxorubicin and Daunorubicin)
when compared to ALDH− cells [39]. These chemoresis-
tant CSCs can then re-establish the tumour following
chemotherapy. However, it is now understood that tu-
mours are composed of one or more CSC hierarchies,
which are composed of multiple CSC-types [40, 41].
With the development of improved analysis tools, new
questions can be asked. For example, it is important for
clinical intervention that the relative therapy-resistance
properties of different types of CSC within the tumour
are assessed. An improved understanding of the relation-
ship between CSC hierarchies and therapy-resistance
can only aid the development of improved technologies.
For example, it is established that SCs and CSCs from
the same tissue type share many of the same self-
renewal and differentiation regulatory mechanisms,
which makes it difficult to target CSCs without dam-
aging the non-malignant SC pool [42]. In a striking
example of this, inhibition of Wnt Signalling as an anti-
cancer treatment had devastating effects on Wnt-
regulated normal development in pre-clinical studies
[41]. A better understanding of the relationship between
CSCs and therapy-resistance is needed to target CSCs
specifically.
Cancer stem cell hierarchies pose additional considerations
for therapy-resistance
Modelling hierarchical CSC organisation is challenging.
As a result, the relationship between CSC hierarchies and
chemoresistance has, arguably, not been studied, which
leaves several key questions open [1]. Specifically, these
key questions are based upon our hypothesis that specific
properties such as chemoresistance may be due to one or
more specific members of a CSC hierarchy (Fig. 2). For
example, which cell do we need to target: therapy-
resistance might be a property of the apex CSC or the pro-
genitor cell, or both? Are CSCs inherently resistant or do
they adapt to therapy over time? How can we identify and
specifically target therapy-resistant CSCs?
When considered in the context of the hierarchical
organization of CSCs, the CSC(s) responsible for
therapy-resistance must be characterized as either apex
CSCs or progenitor CSCs, as this will determine the
logical targeting strategy. Where these are apex CSCs, a
direct target strategy is appropriate, as this should com-
promise the entire hierarchy. However, where these are
found to be progenitor CSCs, the apex CSC that pro-
duces ‘therapy-resistant CSCs’ must also be identified,
studied and targeted. By targeting both cell types simul-
taneously, treatments would ensure the removal of the
CSC/progenitor responsible for therapy-resistant disease
and the apex CSC responsible for their replacement. It is
also important to note that the removal of active CSCs
via chemotherapy stimulates quiescent CSCs into activ-
ity to drive further tumourigenesis [44, 45], Fig. 2]. To
address this challenge, ideally both the active and quies-
cent CSC populations should be targeted. However, qui-
escent cells are by definition difficult to identify, isolate
and study. An alternative for future treatments is a
‘Proliferate to Kill’ strategy, which aims to stimulate the
quiescent CSC population, forcing them to re-enter the
cell cycle, thus exposing them to standard therapeutic
intervention [1].
CSCs employ a collection of therapy-resistance
mechanisms
The description of CSC therapy-resistance mechanisms
in different malignancies in recent years [46] suggest a
generalised vision of CSC therapy-resistance composed
of five components: A) Quiescence; B) Detoxification/
Multi-Drug Resistance (MDR); C) Repair of damaged
DNA; D) Survival; E) Adaptation. As it emerges that
these traits can be shared by CSCs from different malig-
nancies, it is important to consider the nature of the
underlying biology driving these mechanisms. One pro-
spect is regulation by stemness signalling pathways such
as Wnt and Notch, which are known to regulate several
key mechanisms in many different types of SC and CSC.
We propose that it would be prudent to consider each
generalised set of mechanisms, which are now discussed
in detail, when generating CSC models and designing
clinical targeting strategies.
Quiescent CSCs are insusceptible to conventional therapies
Contemporary SC Theory indicates that SCs are orga-
nised as hierarchies and that the apex SC at the top of
the hierarchy can become quiescent [44, 47]. As quies-
cent cells reside outside the cell cycle they are broadly
insusceptible to conventional therapies, which target the
mitotic mechanisms of rapidly-dividing cells [48]. As
such, ‘Quiescence’ is the first CSC therapy-resistance
property. In more recent years, the description of two
further mechanisms, DNA-monitoring and DNA repair
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during quiescence, offers further possibilities for the
complexity of CSC therapy-resistance. In the first set of
studies it has been shown that, rather than simply being
inactive, quiescent SCs actively monitor DNA damage
[49]. The strongest evidence for this mechanism is the
demonstration that loss of key cell cycle regulators such
as p53, p21, p57 or the Retinoblastoma protein impairs
quiescence [50–53]. In addition, two related but separate
studies have indicated that quiescent SCs are primed for
re-entry in to the cycle in a process that involves DNA
repair. Specifically, SCs have been shown to transition
from G0 to G1 of the cell cycle via a ‘GALERT’ state that is
primed for rapid cell cycle re-entry in response to stress
[54]. Complementing this study, it has recently been
shown that quiescent HSCs can accumulate DNA dam-
age and that many of these damaged HSCs are repaired
during cell cycle re-entry rather than being signalled to
undergo apoptosis [55]. These studies suggest that the
quiescent CSC may possess a collection of DNA repair
mechanisms that offer protection against therapeutic
intervention. Despite the difficulty associated with
modelling non-dividing cells, there are indications
that quiescent stem-like populations contribute to at
least some tumours. For example, in primary ovarian
tumours it was demonstrated that CD24+ CSCs were
slower proliferating but more tumourigenic than bulk
cells, suggesting a quiescent, tumourigenic CSC popu-
lation [56]. In addition, quiescent CSCs that survive
chemotherapy can re-enter the cell cycle and re-
establish the tumour [44, 57, 58].
CSCs can detoxify in response to chemotherapy via multi-
drug resistance efflux pumps
It is now established that many CSCs possess MDR
mechanisms that function to detoxify the cell in re-
sponse to chemotherapy. Multi-Drug Resistance is a
collective term for efflux mechanisms that allow chemo-
therapy drugs to be pumped out of the cell before DNA
damage can occur [59]. The best characterised MDR
proteins are the members of the ‘ABC (ATP-Binding
Cassette) transporter’ family, which were originally de-
scribed in bacterial anti-biotic resistance [60]. It was
subsequently found that many cell types possess ABC
transporters. ABC transporters have been described in
many types of cancer cells, where they act to efflux a
wide array of chemotherapeutic drugs [61–63]. Further-
more, ABC transporters have been shown to be
associated with chemoresistance of CSCs in several ma-
lignancies, including ovarian, breast, colon, and non-
small cell lung cancers [64–67]. For example, the ABC
transporters ABCB1 and ABCG2 have been associated
with drug resistance in ovCSCs [64, 68]. As such, MDR
is the second CSC therapy-resistance mechanism. Unfor-
tunately, attempts to develop clinical-targeting of MDR
mechanisms have not been successful to date [69, 70]. It
appears that targeting specific ABC transporters leads to
Fig. 2 Clinical Implications of a Dynamic CSC Hierarchy Model. The model shown proposes that CSC hierarchies are altered by and adapt to clinical
intervention, which poses additional consideration for clinical targeting of CSCs. a Many malignancies are treated by surgical removal of the tumour
mass (debulking) and/or therapy (chemotherapy, radiation-therapy etc.). Contemporary CSC Theory suggests that debulking may cause an awakening
of quiescent CSCs (Red). In parallel, anti-cancer therapies are likely to kill off therapy-sensitive CSCs (Yellow, White). This model proposes that this is likely
to result in the formation of a recurrent tumour that is dominated by therapy-resistant CSCs (Orange) and Progenitors (Green). b This model proposes
that CSC hierarchies are dynamic, particularly when challenged with therapeutic interventions. As a result, identification and targeting of specific
therapy-resistant components within the malignancy may improve the treatment of recurrent disease
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activation of redundant ABC transports to continue the
MDR mechanism, which has hindered their exploitation
as clinical targets [71].
CSCs repair therapy-induced DNA damage via an enhanced
DNA damage response
The third broad category of CSC therapy-resistance
mechanism is the repair of DNA damage induced by
chemotherapy and/or radiotherapy. In addition to those
DNA repair mechanisms expressed by quiescent CSCs
(described above), active cells can elicit a ‘DNA Damage
Response’ (DDR [Reviewed in 72, 73]). There is now a
broad appreciation that many therapy-resistant CSCs
display elevated capacity for detection and repair of
DNA damage, which allows them to survive via resist-
ance to DNA damage induced by cancer therapies.
Platinum-based chemotherapy is based upon forcing the
formation of intra- and inter-strand DNA crosslinks
(ICLs) upon the rapidly-diving cancer cell. ICL-
formation disrupts chromatin structure, resulting in stal-
ling of the replication fork and activation of several DDR
pathways. In sensitive cells, the formation of multiple
ICLs is beyond the cells DDR capacity. As a result, unre-
paired DNA lesions cause cell-cycle arrest via apoptosis
either directly or following DNA replication during the
S phase of the cell cycle [74]. Pathways that have been
shown to be involved in platinum-induced DNA damage
include the Nuclear Excision Repair (NER) and the FA/
BRCA pathway, each of which are now described in de-
tail below. Similar DDR mechanisms are responsible for
resistance to DNA-damage induced by radiotherapy. In
contrast, taxane-based chemotherapies target micro-
tubule dynamics during mitosis. Targeted microtu-
bules cannot be repaired by the cell, which results in
apoptosis via the G2/M checkpoint. Taxane-resistance
is due to mutations in the tubulin sub-units that
comprise microtubules [71], rather than therapy-
resistance mechanisms. As such, taxane-resistance is
not discussed in this review.
Nucleotide excision repair
Intra-strand crosslinks, the most abundant lesion, are
repaired via NER [75], a DDR mechanism that is often
overexpressed in therapy-resistance disease. Mechanis-
tically, NER involves recognition and excision of
single-strand DNA damage. The remaining undamaged
single-strand DNA is used as a template for DNA syn-
thesis, which is followed by ligation to complete the
DDR process. Excision is facilitated by the ERCC1 (exci-
sion repair cross – complementation group 1) protein.
Overexpression of ERCC1 contributes to platinum-
resistance in many cancers, such as ovarian, non-small
cell lung and testicular cancers [76–78]. Recent studies
indicate a link between overexpression of NER proteins
and to CSC chemoresistance [79]. However, this has not
definitively been demonstrated. Overexpression of
ERRC1 may be a mechanism of CSC therapy-resistance,
as elevated mRNA and protein levels of ERRC1 have
been shown in platinum-resistant oral CSCs [80].
However, Wang et al. [81] have demonstrated that NER
protein levels are unrelated to platinum-sensitivity in
ovarian cancer. Furthermore, knockdown of NER factors
compromised NER efficiency, but caused only a minimal
effect on platinum-sensitivity [81].
The fanconi anemia/BRCA DNA damage repair pathway
The detection and repair of ICLs also involves the co-
operation of the Fanconia Anemia (FA) and Breast
Cancer 2 (BRCA) pathways, which are now often re-
ferred to as the FA/BRCA pathway. In this mechanism,
DNA damage is detected and removed by the FA path-
way, and DNA synthesis subsequently completed by the
BRCA-regulated homologous recombination (HR) path-
way [72, 73]. FA is an uncommon disorder characterised
by congenital abnormalities, progressive bone marrow
failure, and cancer susceptibility [82, 83]. FA was found
to be due to abnormalities in a novel DDR mechanism
that became known as the FA pathway. Subsequently,
the FA pathway was found to be associated with the de-
velopment of cancers in FA patients [84] and therapy-
resistance in cancer generally [85, 86]. The FA/BRCA
pathway begins with recognition of ICLs by the FA com-
plementation group complex (FANC), which is com-
posed of multiple FA proteins (A, B, C, D1, D2, E, F, G,
I, J, L, M and N). The connection between the FA path-
ways was originally highlighted by studies showing that
FANCD1 and BRCA2, and FANCS and BRCA1 are the
same genes. Upon ICL detection, the FA pathway is acti-
vated by the monoubiquitination of FANCD2 and
FANCI. FANCD2 is subsequently targeted to the dam-
aged chromatin site where it interacts with the BRCA2
protein, a key regulator of HR [Reviewed in 72, 73]. This
interaction appears to be required for normal HR and
ICL repair. The molecular relationship between monou-
biquitinated FANCD2 and BRCA2 in the HR component
of DDR is not known: it is speculated that the proteins
may cooperate in the timed release of RAD51 at sites of
DNA repair [87, 88].
Activation of the FA/BRCA pathway culminates in re-
pair of ICLs, UV-induced dimers, and double-strand
breaks [89, 90], which plays an important role in the
acquisition of drug resistance in many cancers, such as
multiple myeloma, glioma, cervical and ovarian cancer
[91–94]. Recent studies indicate that overexpression of
FA/BRCA pathway proteins is also linked to CSC che-
moresistance. For example, Meng et al. [34] demon-
strated that platinum resistant ALDH+ ovarian cancer
cells express elevated levels of FA/BRCA DNA repair
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proteins. It is well-established that loss of function
BRCA mutations leads to increased susceptibility to the
development of cancer, particularly in hereditary disease.
In these cases, cancer cell therapy-resistance becomes
dependent upon related, functional DDR mechanisms,
which can be targeted to improve clinical outcomes
[Reviewed in 95]. For example, inhibition of DDR com-
ponents known as ‘PARPs’ (poly ADP ribose polymer-
ases) can enhance therapy-sensitivity in some patients
[Reviewed in 95]. More recently it has been shown that
functional over-expression of BRCA is associated with
therapy-resistance in non-inherited disease [96–99].
Some evidence is emerging that FA/BRCA inhibitors
such as the FDA approved Bortezomib can improve che-
moresponse in otherwise refractory disease [100, 101].
CSCs employ anti-apoptotic mechanisms to promote survival
in response to clinical intervention
The accumulation of substantial DNA damage results in
the activation of apoptotic mechanisms, which must be
inhibited in therapy-resistant cells. For example, it is
now well-established that evasion of apoptosis is one of
the major mechanisms of ovarian cancer associated
platinum-resistance [102, 103]. Anti-apoptosis mecha-
nisms contribute to therapy-resistance directly by block-
ing cell death and indirectly by providing time for
enhanced DDR mechanisms to repair therapy-induced
DNA damage. These anti-apoptotic mechanisms include
the extrinsic and intrinsic pathways, and the tumour
suppressor protein p53, each of which will now be
discussed. Collectively, these represent a fourth, pro-
survival mechanism for CSC therapy-resistance.
The extrinsic apoptotic pathway
The extrinsic apoptotic pathway is characterised by de-
tection of death signals by ‘Death Receptors’. Death re-
ceptors are cell-surface expressed, and belong to the
superfamily of tumour necrosis factor receptors (TNF-R)
that are activated by TNF family ligands. The best-
characterized death receptors include FAS (APO-1/
CD95), TNF receptor 1 (TNFRI), TNF-related apoptosis-
inducing ligand-receptor 1 (TRAIL-R1) and TRAIL-R2.
Upon stimulation by the FAS ligand, FAS trimerises,
which allows intracellular binding of the adaptor-protein
FADD to the receptor. FADD in turn serves to recruit
pro-caspases-8 and −10 into the complex, which ultim-
ately activates downstream caspases, leading to apoptosis
[104, 105]. Cancer cells have evolved numerous strat-
egies to resist drug-induced cell death via the extrinsic
pathway. For example, surface expression of death re-
ceptors have been shown to be downregulated or absent
in drug resistant tumours, including platinum-resistant
ovarian cancer [106]. Upregulation of FAS has been
shown to reverse platinum-resistance in ovarian cancer
[107]. While FAS plays a pro-apoptotic role in SCs, it
appears to promote survival in CSCs [108]. Furthermore,
upregulation of the adaptor-protein FADD has been
shown to sensitise ovarian cancer cells to platinum treat-
ment [109]. Although little is known yet about evasion
of apoptosis as a possible CSC chemoresistance mechan-
ism, data indicates that CSCs resist cell death via the
extrinsic pathway. For example, an upregulation of
TRAIL-R1 leads to chemoresistance in colon CSCs
[110]. Several mechanisms have been identified in mam-
malian cells for the induction of apoptosis. These mech-
anisms include factors that lead to perturbation of the
mitochondria leading to leakage of cytochrome C or fac-
tors that directly activate members of the death receptor
family. Epothilones are a new group of compounds with
action mechanisms similar to taxanes. In an ovarian can-
cer model Epothilone A and B have been shown to in-
duce cell death via a decrease in mitochondrial
membrane potential [111]. This may represent a future
clinical strategy.
The intrinsic apoptotic pathway
The intrinsic apoptotic pathway induces cell death by
affecting mitochondrial permeability, which leads to the
release of cytochrome C to activate caspases. Among its
many regulators, the pathway is primarily regulated by
members of the BCL-2 family [112, 113]. The protein
BCL-2, the founding member of the BCL-2 family, pri-
marily mediates its pro-survival effects by binding to the
pro-apoptotic partners BCL2-associated-X-protein (BAX)
and BCL-2 homologous antagonist killer (BAK), which de-
creases release of cytochrome C from the mitochondria.
BCL-2 family members are overexpressed in many solid
tumours and have been linked to tumourigenesis, cancer
cell survival and chemoresistance [109, 114, 115]. Recent
studies show that BCL-2 overexpression is also linked to
CSC chemoresistance. For example Madjd et al. [116]
showed that the protein BCL-2 is highly expressed in
CD44+/CD24-/low breast CSCs. To date, little is known
about the mechanism, but CSC research suggests that
these proteins can affect chemoresistance through induc-
tion by other signalling pathways required for CSC sur-
vival. For example, Ma et al. [117] demonstrated that
BCL-2 induction by AKT1 may be a mechanism by which
CSCs can mediate chemoresistance.
The role of p53 in apoptosis
The tumour suppressor p53 acts as the overall regulator
of the activation of apoptotic processes in response to
the detection of unrepairable DNA damage [118, 119].
Like BRCA, ‘loss of function’ p53 mutations are associ-
ated with the development of various malignancies,
while its over-expression in cancers with functional
DDR mechanisms is associated with therapy-resistance.
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In addition, numerous chemotherapy drugs exert their
function through targeting p53-related signalling path-
ways. Therapy-induced DNA damage leads to activation
of p53, which binds to the regulatory sequences of a
number of target genes to initiate a program of cell cycle
arrest and DDR. If the drug-induced damage cannot be
repaired completely, over-activation of p53 leads to
tumour growth stagnation or even apoptosis via the in-
duction of the intrinsic and extrinsic apoptosis pathways
[120–122]. Loss of p53 function occurs during the devel-
opment of most, but not all, tumour types. This results
in tumour cells being able to escape drug-induced apop-
tosis [122]. A downregulation of p53 has been shown in
platinum-resistant ovarian cancer [109]. However, recent
studies show an alternative mechanism where p53 over-
expression is linked to CSC chemoresistance. For ex-
ample, it was shown that overexpression of p53
sensitises glioblastoma CSCs to drug treatment trough
enhanced apoptosis [123].
CSC hierarchies can adapt to survive clinical intervention
The principles governing the relationship between CSC
hierarchies and therapy-resistance are poorly under-
stood. Our most recent work has highlighted that
therapy-resistance is not the property of all CSCs within
a hierarchy: therapy-resistance can be CSC- and drug-
type specific (Ffrench et al. Unpublished). Furthermore,
we have found that progenitor CSCs can adapt to
platinum-treatment by altering their potency (producing
a different cell type via differentiation). This data indi-
cates that, in at least some cases, CSC models contain
more than one type of CSC, some of which are therapy-
sensitive and some therapy-resistant. This data suggests
a model (Fig. 2) where the treatment-naïve CSC hier-
archy can contain therapy-sensitive and therapy-resistant
CSCs. Post-intervention, sensitive CSCs are killed off,
which results in a recurrent tumour and CSC hierarchy
with increased numbers of therapy-resistant CSCs. In
addition, removal of the tumour by surgical de-bulking
may awaken quiescent CSCs to synergistically enhance
the production of the therapy-resistant recurrent malig-
nancy. This may explain why initial pre-clinical success
has not broadly translated to the clinic (Fig. 2). As such,
it is important to identify, study and target the specific
CSCs responsible for specific types of therapy-resistance
within specific malignancies.
Altered CSC-related signalling pathways in therapy-
resistance
SC function is regulated by a number of signalling pathways
such as Wnt and Notch [1], which are commonly dysregu-
lated in therapy-resistant CSCs [124]. However, targeting of
these pathways can have adverse effects on similarly-
regulated non-malignant SC pools. The involvement of
stemness signalling pathways such as Wnt and Notch in
CSCs from multiple different types of malignancy is
now described and suggests an important role in CSC
therapy-resistance. It is tempting to speculate that these
stemness signalling pathways may facilitate coordinated
CSC therapy-resistance mechanisms such as quies-
cence, detoxification (MDR), repair (DDR), survival
(anti-apoptosis) and adaptation.
The Wnt signalling pathway has been shown to play
an important role in the maintenance of SCs and lineage
differentiation in a wide array of tissues and organs
[125]. Altered expression of this pathway has been
shown in many cancers, such as ovarian, breast and
colon [126–128]. While the precise mechanism has not
been fully elucidated, elevated levels of Wnt Signalling
modulator β-catenin have been shown to actively con-
tribute to platinum-resistance in ovarian cancer cells
[129]. Hepatic CSCs have been shown to exhibit en-
hanced platinum-resistance that could be reversed by
lentiviral microRNA knockdown of β-catenin [130]. It is
not clear how Wnt signalling mediates CSC chemoresis-
tance but upregulation of ABC transporters presents one
potential mechanism: ABCG2 resistance to both plat-
inum and taxanes could be reversed by β-catenin siRNA
knockdown in c-kit+ ovCSCs [131]. Furthermore, it was
shown that inhibition of the Wnt signalling pathway, in
combination with platinum, induced cytotoxicity and
cell cycle arrest in a higher percentage of primary ovar-
ian samples than with single drug treatment [126]. Be-
cause of the molecular similarity between SCs and CSCs
from the same region of the body it is very difficult to
target CSCs without damaging the non-malignant SC
pool, a side-effect that would have devastating growth
and repair consequences for the patient. In a stark ex-
ample of this, Wnt inhibition as an anti-cancer treat-
ment has been shown to have devastating effects on
Wnt-regulated normal intestine development in pre-
clinical studies [43].
The Notch signalling pathway plays a role in both
CSC maintenance and drug resistance in many malig-
nancies [Reviewed in 1]. For example, Notch proteins
have been identified to be upregulated in ovCSCs [132].
Furthermore, in the same study a γ-secretase inhibitor
(GSI), which inhibits Notch signalling, was shown to
erase CSCs and increase tumour sensitivity to platinum-
agents. Most importantly, it was found that platinum/
GSI combination compared to single treatment was
more effective to eliminate both CSCs and the bulk of
tumour cells, indicating that a dual combination target-
ing both populations is needed for tumour eradication.
In addition, the group found that the Cisplatin/GSI com-
bination therapy has a synergistic cytotoxic effect in
Notch-dependent tumour cells by enhancing the DNA-
damage response, G2/M cell-cycle arrest, and apoptosis
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[132]. The superior effectiveness of a combination of
chemotherapy drug and Notch-targeting CSC-inhibitor
(GSI) compared to monotherapy in an otherwise refrac-
tory disease, has also been reported in pancreatic metas-
tasis [133]. As such, it is emerging as an early paradigm
for how CSC-targeting should be conducted as part of
an overall treatment [1].
In the absence of other evidence, stemness signalling
pathways appear to be likely candidates for a role in co-
ordinating the multiple responses of therapy-resistant
CSCs to clinical intervention. We propose that all of the
mechanisms described in this section should be consid-
ered during analysis of CSC models. An improved un-
derstanding of the mechanisms of CSC therapy-resistant
may facilitate development of novel treatment strategies.
This is discussed in detail later. However, before they
can be analysed, CSC models must be built.
CSC discovery: identifying the therapy-resistant
components of CSC hierarchies
While it is well-accepted that CSC-targeting must be
assessed as a novel therapeutic avenue, little progress
has been made in improving survival rates in the clinic.
We believe that this is partially due to our failure to
identify specific therapy-resistant component in the con-
text of CSC hierarchies. We hypothesise that it cannot
simply be assumed that each component of a CSC hier-
archy contributes to therapy-resistance equally. Address-
ing this, we have recently built a novel, four-component
CSC hierarchy and assessed platinum- and taxane-
resistance in each, individual CSC type. Our data indi-
cate that platinum-resistance is the property of only one
CSC-type within that hierarchy and that all four compo-
nents are taxane-sensitive. Additionally, we found that
repeated exposure to platinum results in an altered hier-
archy with altered plasticity, with a different CSC type
taking the ‘Apex’ position at the top of the hierarchy
(Ffrench et al. Unpublished). These findings impose new
considerations upon CSC research, which are now
discussed in the context of our perspective on CSC
Discovery and clinical targeting.
CSC discovery
We propose that therapy-resistant CSC Discovery
should be conducted in paired therapy-sensitive and
therapy-resistant models. In our opinion, this is one of
most over-looked factors in CSC Discovery and is a large
determinant of success [1]. For a detailed description of
our approach to CSC Discovery the reader is referred to
[1]. Briefly, CSC Discovery should begin with a model
that addresses a clinical problem. For example, if a par-
ticular malignancy is characterised by high levels of mor-
tality due to platinum-resistance, CSC Discovery is best
undertaken in paired cell models of platinum-sensitivity
and platinum-resistance in that malignancy. Many avail-
able cell line models are therapy-naïve and can be easily
rendered therapy-resistant by exposure to increasing
doses of the therapy over time. While these cell lines are
not a perfect facsimile of in vivo disease, many studies
have demonstrated that they are readily available sources
for CSC Discovery. Broadly, CSCs have been successfully
identified through screening for SC markers such as
ALDH and ‘Cluster of Differentiation’ (CD44, CD133
etc.), and SC properties such as efflux (Hoechst dye
efflux ‘side population’ assay) and non-adherent growth
(‘spheroid formation’) assays. Once identified and vali-
dated, these CSCs are available for in vivo validation in
clinical samples. Subsequently, CSC hierarchy relation-
ships can be elucidated as now described.
Building a therapy-resistant hierarchy
The rapid advances in flow cytometry-based technology
in recent years mean that building CSC hierarchies is
now much more achievable than it has been in the past.
In this regard, we have found the SCAD assay particu-
larly useful [1]. In this assay, single cells positive and
negative for identified SC markers are allowed to form
colonies, which are then tested for the presence of the
marker: where both positive and negative cells are found
in the colonies, this is suggestive of SC properties.
Importantly, SCAD assays can easily be scaled to include
two or more markers. For example, where two SC
markers (A and B) are identified in screens, a four com-
ponent hierarchy (A+/B+, A−/B−, A+/B−, A−/B+) can eas-
ily be built. Characterising of the colonies formed allows
the relationship between each CSC type to be estab-
lished, and an accurate model of the CSC hierarchy to
be identified, which may include the apex CSCs, and
inter-related and independent progenitors [1]. For ex-
ample, and SCAD approach has recently been used to
describe an ovCSC hierarchy based on the expression of
ALDH and CD133 [38]. In this model, highly tumouri-
genic ALDH+CD133+ CSCs give rise to somewhat less
tumourigenic ALDH+CD133− CSC/progenitors, which
in turn give rise to non-tumourigenic ALDH−CD133−
cells. Once validated in standard xenograft-formation as-
says, the platinum-resistant component of this hierarchy
could be identified, and the mechanism identified as
now described.
Identification of the therapy-resistant component of a CSC
hierarchy, and its mechanism
The standard approach to the identification of therapy-
resistant cells is to test populations for survival following
treatment with chemotherapy or radiotherapy. As such,
measuring the relative contribution to resistance of each
cell type in a CSC hierarchy appears to be a daunting
task. However, flow cytometry’s ability to accurately
Gasch et al. Molecular Cancer  (2017) 16:43 Page 9 of 15
measure the relative proportion of sub-populations
within a CSC hierarchy provides an elegant solution.
This approach can be adapted for CSC hierarchy re-
search purposes by simply assaying the post-treatment
CSC hierarchy for the presence of its original SC
markers via flow cytometry. This approach easily facili-
tates quantification of the relative therapy-resistance of
each individual CSC type within the hierarchy, which is
a strong indication of their proportional contributions to
therapy-resistance. A therapy-sensitive model can be
assessed pre- and post- acute treatment, and the resist-
ance of specific CSC populations highlighted by an in-
crease in their respective proportions. Furthermore,
chronic treatment of the sensitive model over time can
be used to generate a paired resistant model, which can
be reanalysed before and after acute treatment. Such a
matrix of comparisons will point towards the identity of
the intrinsically and adaptively resistance cell popula-
tions within the models being investigated.
This analysis can be carried out on both the entire
hierarchy or individual CSC types present in sufficient
numbers to allow purification for assays. As a caveat, we
have noted that the quantitative tolerance of resistant
CSC types can be higher when assayed in isolation com-
pare to within the hierarchy as a whole. This is likely
due to the absence of pro-apoptotic signalling from
therapy-sensitive CSCs that are absent when a therapy-
resistant CSC is assayed in isolation. Once identified, the
specific mechanisms expressed by individual therapy-
resistant CSC types can be identified using standard
gene expression assay or RNAseq approaches. For
example, our most recent work has highlighted elevated
expression of MDR, DDR and anti-apoptotic mechanisms
in platinum-resistant CSCs compared to platinum-
sensitive CSCs from the same hierarchy (Ffrench et al.
Unpublished). As a final consideration, we have found that
specific MDR, DDR and anti-apoptotic mechanisms are
expressed in treatment-naïve and platinum-adapted
models, as discussed above. It is clear that this observation
would likely have been missed had our work been under-
taken in a single model. This is strong evidence for the
undertaking of CSC Discovery in paired therapy-sensitive
and therapy-resistant models.
Clinical perspective: towards targeting of therapy-
resistant CSCs
Early CSC Theory highlighted several principles on
which clinical targeting of CSCs should be based. At the
time, there was great hope that CSC targeting in the
clinic could dramatically improve the prognosis of re-
fractory disease. In spite of this, the translation of CSC-
targeting to the clinic has not been as efficient as had
been hoped. In this section we will describe some of the
clinical implications of our contemporary understanding
of CSC Theory. In particular, we will discuss how our
clinical-targeting strategies must allow for the model of
CSC hierarchies as moving, rather than static, targets.
Clinical considerations from early CSC theory
CSC theory as presented by Reya et al. [25] highlighted
several clinical implications of relevance to our under-
standing of how CSCs influence therapy-resistance.
Firstly, CSCs were identified as clear clinical targets due
to their role in primary, metastatic and recurrent dis-
ease. Secondly, low numbers of CSCs persisting post-
intervention were sufficient to drive recurrent disease.
As the CSCs responsible for this repopulation were by
definition therapy-resistant, it was suggested that this
property would be passed on to the entire progeny of
the tumour reinitiating CSCs. This theory, therefore,
could account for the higher levels of therapy-resistance
found in recurrent disease compared to primary tu-
mours. Thirdly, CSCs were originally thought to be
rapidly-dividing and thus particularly susceptible to
standard interventions, which are designed to target rap-
idly dividing (cancer) cells. The fact that this was not the
case in the clinic provided evidence that CSCs possessed
strong therapy-resistance properties, which were postu-
lated as mechanisms such as enhanced MDR and DDR.
Finally, one of the most contentious suggestions at this
point was that CSCs were not simply one of many differ-
ent types of tumour-initiating cell but were the only
known tumour-initiating cell. Indeed, to this day an effi-
cient, tumour-initiating cell de-void of stem cell proper-
ties has not been reported to our knowledge. This
implication presents CSCs as the primary culprit for cir-
culating tumour cells that facilitate metastasis. As such,
targeting CSCs should produce the additional benefit of
reducing metastasis. These concepts were widely ac-
cepted by the cancer research community, which held
out great hope that CSC targeting could be developed as
part of a combined cancer treatment strategy, which
would be particularly suited to refractory disease. Stra-
tegically, it was believed that CSCs should be targeted
during primary treatment to prevent metastasis and re-
currence and the development of therapy-resistance.
This model suggested a strategy where cancer treatment
could be improved by removing stemness properties from
CSCs globally. This so called ‘Forced Differentiation’ ap-
proach has been best examined using differentiation mor-
phogen all-trans retinoic acid (ATRA), which has being
explored in a variety of haematological malignancies, in-
cluding myelodysplastic syndromes, multiple myeloma
and chronic myelogenous leukemia [134, 135]. Alone or
in combination with other therapies, ATRA is also being
investigated in a variety of solid tumours including pros-
tate cancer, breast cancer and glioma [136–138]. Although
pharmacological doses of retinoids have proven effective
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in the treatment of haematological malignancies
[139], clinical trials in the prevention and treatment
setting in a number of solid tumours have failed to
show significant benefit to date [68, 140]. For ex-
ample, clinical trials in breast cancer have shown
moderate potential, but consistently low response
rates of below 30% [141, 142]. This is one example
that illustrates how inefficient CSC-targeting ap-
proaches have been to date. This suggests that target-
ing CSCs globally may not be an efficient strategy in
all but a few, specific malignancies. In contrast, our
contemporary understanding of CSCs suggest that
specific targeting strategies may be more successful,
which is now discussed in detail.
Contemporary CSC theory suggests New considerations
for clinical intervention
The important CSC-targeting principles highlighted by
Reya et al. [25] provide the foundation upon which con-
temporary CSC Theory has been built. Early CSC theory
suggested that tumour heterogeneity could be broadly
divided in to two cell types, namely CSCs and differenti-
ated cells. In the intervening years it has become clear
that heterogeneity in at least some, and perhaps many or
all, malignancies is due to the presence of multiple CSC
types arranged as hierarchies [26]. There is clear evi-
dence that the identification and targeting of a single
CSC-type has potential as a clinical strategy. Perhaps the
most striking example of this was described in ovarian
cancer, where targeting of Notch signalling in ovCSCs
resulted in platinum-based elimination of disease in an
animal model of otherwise refractory disease [132].
However, a large collection of similar studies has not
been produced in other malignancies. In addition, there
have been few successes in the clinic. We propose that
one of the key factors behind this failure is the complex
hierarchical organisation of CSCs, which complicates
clinical targeting. Rather than looking for a ‘needle in a
haystack’, which was challenging enough, it appears that
we must now locate and target a specific, clinically-
relevant needle in a collection of similar needles
within the haystack. Complicating this further, it ap-
pears that CSC hierarchies are altered by and adapt
in response to our interventions, making them com-
plex moving targets.
Clinical implications of CSC hierarchy dynamics
Contemporary CSC Theory proposes that tumour het-
erogeneity is due to the presence of multiple CSC
Hierarchies within a single tumour [26]. In addition to
the concepts described here, evidence is emerging for
other forms of plasticity such as the conversion of non-
CSCs to CSCs phenotypes in defined circumstances
[143]. This more complex view of in vivo CSC
organisation has important considerations for clinical
targeting. The most obvious principle is that the apex
CSC(s) should be targeted in order to compromise the
entire hierarchy. As discussed above, apex CSCs might
only be readily targetable when they are active during
early tumourigenesis, as targeting the quiescent state is
currently unachievable. This suggests a strategy where
targeting of CSC progenitors should substantially com-
promise tumourigenicity. However, as quiescent (apex)
CSCs are largely insusceptible to anti-mitotic cancer
treatments, targeting CSC progenitors is likely to result
in an awakening of the quiescent CSC pool and rapid re-
generation of the tumour (Fig. 2). This may partially
explain why successful primary intervention can be
followed months later by substantial, aggressive recur-
rent disease.
This model of recurrent disease is based upon an as-
sumption that awakened quiescent CSCs reconstitute
the primary malignancy as recurrent disease. However,
in our lab we have observed that therapeutic interven-
tion can alter the CSC hierarchy, which has important
considerations for clinical targeting. Our data indicate
that only some components of a CSC hierarchy are re-
sistant to platinum. As a result, after only a few days the
hierarchy is altered: the sensitive CSC populations have
been dramatically reduced in size, leaving a proportion-
ally larger resistant CSC population (Fig. 2). As a result,
after only a few days of platinum treatment the CSC
hierarchy observed post-intervention is substantially differ-
ent to the treatment-naïve model (Fig. 2). As such, we hy-
pothesise that CSC hierarchies within the tumour are not
‘fixed targets’: in terms of CSC organisation, the primary
tumour can be quite different to the recurrent tumour.
This may partially explain why primary disease can be sen-
sitive and recurrent disease resistant to the same therapy.
Conclusion
Catching moving targets: elucidation and targeting of
dynamic CSC hierarchies
Considerable advances need to be made before efficient,
clinically-relevant targeting of entire CSC hierarchies
can be achieved. To date, very little research has been
carried out to elucidate the relationship between CSC
hierarchies and therapy-resistance. We have argued that
therapy-resistance within CSC hierarchies can be highly
specific: therapy-resistance can be the property of a spe-
cific type of CSC and not a global property of the hier-
archy; CSCs that are resistant to one type of therapy
(e.g. platinum) can be sensitive to another (e.g. taxanes);
CSC hierarchies can be altered as sensitive populations
are killed off by our interventions; this can result in sub-
stantial alterations to the CSC hierarchy, including the
moving of a different CSC type to the apex position.
While these observations must be tested and validated
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in other malignancies, this suggests that a broader, more
specific view of CSC Discovery and targeting may be
more successful that global targeting approaches. This
type of specificity is in line with the personalised medi-
cine approach, which has been highly successful in the
clinic in malignancies such as breast cancer.
Dynamic CSC hierarchies are best modelled using
paired-models of sensitive and resistant disease that are
specific for different therapeutic-interventions. The obvi-
ous application for this is in the treatment of therapy-
resistant breast cancer. In recent years, breast cancer
treatment has been dramatically improved by the identi-
fication of sub-types within the disease that respond best
to specific therapies. However, in contrast, the under-
standing of the specific CSC hierarchies associated with
each sub-type of breast cancer is sparse. The identifica-
tion and targeting of the specific CSC hierarchies re-
sponsible for therapy-resistance in different types of
breast cancer may facilitate the development of im-
proved treatment strategies. In addressing this, it is
important to note that the CSC hierarchies in each sub-
type may be quite different from one another and altered
post-intervention. In addition, the success in breast can-
cer suggests that the specific targeting of sub-types
within malignancies can enhance outcomes in other re-
fractory malignancies. It seems clear that there is great
potential for the exploitation of the specificities of CSC
types within sub-types of malignancy as both bio-
markers for early detection and targets for the treatment
of refractory disease.
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